Literature DB >> 26178503

[Safety of plasma exchange therapy in patients with anti-NMDA receptor encephalitis].

Yan Zhang1, Daiquan Gao2, Hong Ye2, Yingying Su2.   

Abstract

OBJECTIVE: To explore the safety of plasma exchange (PE) therapy in patients with anti-NMDA receptor encephalitis.
METHODS: Prospective reviews were conducted for the adverse events and therapeutic efficacies of PE therapy in 9 patients with anti-NMDA receptor encephalitis admitted into neuro-intensive care unit from January 2012 to January 2015.
RESULTS: A total of 54 PE procedures were performed. The NMDA receptor antibody titer of cerebrospinal fluid (CSF) and/or sera in 9 patients (100%) decreased or turned negative. Five patients (55.5%) demonstrated clinical improvement after PE therapy. And clinical complications included frequent involuntary movements, hypotension, coagulation of PE channel, febricity, allergic response and errhysis around peripheral venous access.
CONCLUSION: PE is effective, safe and well-tolerated in patients with anti-NMDA receptor encephalitis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26178503

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  2 in total

1.  Successful treatment of anti-NMDA receptor encephalitis with a prompt ovarian tumour removal and prolonged course of plasmapheresis: A case report.

Authors:  Elzbieta Rypulak; Michal Borys; Pawel Piwowarczyk; Magdalena Fijalkowska; Beata Potrec; Justyna Sysiak; Janusz Spustek; Alicja Bartkowska-Sniatkowska; Jan Kotarski; Waldemar A Turski; Konrad Rejdak; Miroslaw Czuczwar
Journal:  Mol Clin Oncol       Date:  2016-10-19

2.  Successful treatment of anti-NMDA receptor encephalitis with early teratoma removal and plasmapheresis: A case report.

Authors:  Monica Gomes Ferreira; Victoria Lapresa Alcalde; María Helena García Sánchez; Lourdes Hernández Hernández; María José Doyague Sánchez
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.